UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042876
Receipt number R000048938
Scientific Title Clinical study on the interrelationship between liver, heart, and lung in portal hypertension
Date of disclosure of the study information 2021/01/04
Last modified on 2020/12/30 12:51:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study on the interrelationship between liver, heart, and lung in portal hypertension

Acronym

The interrelationship between liver, heart, and lung in portal hypertension

Scientific Title

Clinical study on the interrelationship between liver, heart, and lung in portal hypertension

Scientific Title:Acronym

The interrelationship between liver, heart, and lung in portal hypertension

Region

Japan


Condition

Condition

Portal hypertension

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the frequency of cardiac function abnormalities and pulmonary hypertension in patients with portal hypertension, changes in cardiac function and pulmonary hypertension after treatment of complications of portal hypertension, and to clarify the clinical significance of cirrhotic cardiomyopathy and portopulmonary hypertension.

Basic objectives2

Others

Basic objectives -Others

Epidemiological survey

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Frequency of cirrhotic cardiomyopathy and portopulmonary hypertension in patients with portal Hypertension and at 3 months and 1 year

Key secondary outcomes

a. Examine the relationship between liver reserve values (blood chemistry, Child-Pugh score, MELD score, and liver elasticity) and cardiac and portopulmonary hypertension factors.
b. Examine the relationship between portal hemodynamic severity (hepatic venous pressure gradient, Doppler flow factors in portal vein and portosystemic shunt) and cardiac function factors and pulmonary hypertension factors.
c. To examine changes in cardiac function and pulmonary hypertension factors after treatment of complications associated with portal hypertension.
d. Examine the relationship of prognosis to cardiac function and pulmonary hypertension factors.
e. Examine differences in endothelin, cytokines, and BMP9

by angiographic site and changes after treatment.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients scheduled for treatment of complications associated with portal hypertension (splenomegaly, portal hypertension, esophagogastric varices, refractory ascites) or patients suspected of having cirrhotic cardiomyopathy or portopulmonary hypertension due to respiratory distress, etc.
2) Age 20 years or older
3) Patients who have received sufficient explanation about the study after receiving sufficient explanation about their medical conditions and treatment methods, and who have obtained written consent of their own free will with sufficient understanding.

Key exclusion criteria

(1) Patients whom the principal investigator or sub-investigator judges to be inappropriate as subjects.
(2) Patients for whom outpatient follow-up at our hospital is difficult.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Kato
Middle name
Last name Naoya

Organization

Chiba University Graduate School of Medicine

Division name

Deartment of Gastroenterology

Zip code

260-8677

Address

1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

TEL

0432227171

Email

takakon@chiba-u.jp


Public contact

Name of contact person

1st name Kondo
Middle name
Last name Takayuki

Organization

Chiba University Hospital

Division name

Department of Gastroenterology

Zip code

260-8677

Address

1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

TEL

0432227171

Homepage URL


Email

takakon@chiba-u.jp


Sponsor or person

Institute

Chiba University

Institute

Department

Personal name



Funding Source

Organization

N/A

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Chiba Univesity Graduate School of Medicine, IRB

Address

1-8-1, Inohana, Chuo-ku, Chiba, Japan

Tel

0432227171

Email

inohana-rinri@chiba-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 10 Month 12 Day

Date of IRB

2020 Year 12 Month 22 Day

Anticipated trial start date

2021 Year 01 Month 04 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

N/A


Management information

Registered date

2020 Year 12 Month 30 Day

Last modified on

2020 Year 12 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048938


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name